have been described in humans, ranging in size from Ͻ 300 kDa to Ͼ 800 kDa (2).
Lipoprotein [a] (Lp[a]
) is a LDL-like lipoprotein that has been associated with increased risk of coronary heart disease, stroke, and restenosis (1) . Lp [a] , which closely resembles LDL in lipid composition, contains a single apolipoprotein B-100 (apoB-100) molecule and an additional apolipoprotein, called apolipoprotein [a] (apo[a]), which is connected via a disulfide linkage to apoB-100 (1) . Apo [a] is a polymorphic glycoprotein that contains repeating domains of varying length that are homologous to kringle IV of plasminogen. More than 30 different isoforms of apo [a] have been described in humans, ranging in size from Ͻ 300 kDa to Ͼ 800 kDa (2) .
Plasma levels of Lp [a] vary greatly between individuals, from Ͻ 1 mg/dl to Ͼ 100 mg/dl (2) . The source of most of this variability in plasma concentrations is variability in the production rate of Lp[a] (3, 4) , which, in turn, is controlled largely by the apo[a] gene locus (5) . Apo[a] is synthesized by hepatocytes and rapidly associates with LDL after secretion to form Lp [a] in the sinusoids of the liver (2, 6) . Although the steps involved in Lp[a] production are known, the major mechanisms involved in Lp [a] clearance from plasma are not currently known. It has been suggested that the kidney might play a major role in Lp[a] clearance, after several clinical studies reported increased plasma Lp[a] levels in patients with renal failure (7, 8) . In addition, Kronenberg et al. (9) used measurements of renovascular arteriovenous differences in Lp [a] plasma concentrations in patients without renal insufficiency to demonstrate that the human kidney may play an active role in Lp[a] catabolism.
Several receptors that mediate the binding and uptake of lipoproteins containing apoB-100 have been proposed as receptors for Lp [a] catabolism. These include the LDL receptor (LDLR) (10) (11) (12) (13) (14) (15) , megalin/gp330 (16) , the LDL receptor-related protein (LRP) (17) , and the VLDL receptor (18) . The latter two receptors can mediate binding to lipoproteins through apoE. According to the secretioncapture model, apoE that is secreted by the liver rapidly binds to remnants associated with heparan sulfate proteoglycans. These captured lipoproteins are then cleared by receptor-mediated endocytosis (19) . ApoE has been proposed to play a similar role in Lp [a] catabolism (20) .
The current studies were designed to test potential pathways responsible for Lp [a] uptake in mice through the use of a radioiodinated, intracellularly trapped ligand, tyramine cellobiose (TC), which was covalently attached to human Lp [a] and injected into mouse models in the C57BL/6 genetic background. Our results demonstrate that in this model, the liver is the major organ responsible for the plasma clearance of Lp [a] and that the kidney plays a very minor role under normal conditions. In addition, we examined the role of the LDLR, apoE, and the asialoglycoprotein receptor (ASGPR) in the clearance of Lp [a] in mice. These studies show that the LDLR, apoE, and the ASGPR do not have a major role in Lp[a] catabolism in mice. Lastly, we demonstrated that the administration of excess apo [a] can effectively block the plasma clearance of Lp [a] , suggesting that it is the apo[a] moiety that mediates the plasma clearance of Lp [a] .
METHODS

Animals
Wild-type C57BL/6, LDL receptor-deficient ( Ldlr Ϫ / Ϫ ), and apoEdeficient ( Apoe Ϫ / Ϫ ) mice were obtained from Jackson Laboratories (Bar Harbor, ME). Mice were maintained on a chow diet under a 12 h light/dark cycle.
Isolation of lipoproteins and apo[a]
Lp[a] was isolated from single-donor plasma as described previously (3, 4, 21) . Briefly, plasma was immediately brought to 0.01% NaN 3 , 0.01% Na 2 EDTA, and 1 mM benzamidine and adjusted to a density of 1.21 g/ml, and total lipoproteins were isolated by ultracentrifugation. The total lipoprotein fraction was dialyzed against phosphate buffer (0.1 M sodium phosphate, 0.01% NaN 3 , 0.01% Na 2 EDTA, and 1 mM benzamidine, pH 7.4) and then applied to a lysine-Sepharose column (Amersham Pharmacia) equilibrated with phosphate buffer. The column was then washed with phosphate buffer, and the unbound fraction, which contained LDL, was collected. The bound fraction, which is composed mostly of Lp[a], was eluted with phosphate buffer containing 100 mM -aminocaproic acid (ACA). This fraction was brought to 7.5% (w/w) CsCl and centrifuged in a Beckman 60Ti rotor at 50,000 rpm and 15 Њ C for 27 h. The self-forming density gradient was pumped from the centrifuge tubes. Those fractions containing purified Lp[a] were pooled and dialyzed against PBS (0.1 M NaCl, 0.01 M sodium phosphate, 0.01% NaN 3 , 0.01% Na 2 EDTA, and 1 mM benzamidine, pH 7.4). The unbound fraction from the lysine-Sepharose column was dialyzed against histidine buffer (0.2 M NaCl, 0.025 M histidine, and 0.01% Na 2 EDTA, pH 6.0) and applied to a column containing PBE94 (Bio-Rad) equilibrated with histidine buffer. The column was washed with histidine buffer, and the unbound fraction, which contained LDL, was collected and dialyzed against PBS. This fraction was concentrated using an Amicon stirred pressure cell, and the density was then adjusted to 1.35 g/ml with NaBr. Five milliliters of this solution was placed into 25 ml Beckman 60Ti centrifuge tubes and overlaid with a 0-25% NaBr gradient. The tubes were centrifuged for 90 min at 15 Њ C and 50,000 rpm. The density gradient was pumped from the centrifuge tubes, and those fractions containing purified LDL were pooled and dialyzed against PBS.
Apo[a] was prepared by a modification of the procedure described by Edelstein et al. (22) . Lp[a] was brought to a final concentration of 100 mM ACA and 2 mM dithioerythritol and incubated at room temperature for 1 h. The reaction mixture was dialyzed against PBS for ‫ف‬ 1 h and adjusted to a density of 1.3 g/ml with NaBr. Approximately 5 ml of the density-adjusted reaction mix was placed into a Beckman 60Ti centrifuge tube and overlaid with a 10-25% NaBr gradient to a volume of 25 ml. This was centrifuged at 50,000 rpm and 15 Њ C for 90 min to separate apo[a] from the LDL released by reduction and intact Lp [a] . The density gradient was pumped from the centrifuge tubes, and those fractions containing purified apo[a] were pooled, dialyzed against PBS, and concentrated using Vivaspin concentrators (Vivascience).
The 
Radioactive labeling of proteins
Lipoproteins, apo [a] , and asialofetuin (from fetal calf serum; Sigma) were directly iodinated with either Na 131 I or Na 125 I (New England Nuclear) using a modification of the iodine monochloride procedure (4); alternatively, TC was iodinated with either Na 131 I or Na 125 I and then chemically coupled to LDL or Lp[a] using the procedure described by Pittman and Taylor (23) . Typically, 0.1 mol of TC was iodinated using Iodobeads (Pierce) and then chemically coupled to ‫ف‬ 5 mg of protein with 0.1 mol of cyanuric chloride. The purity of the radiolabeled preparations was verified using SDS-PAGE and 1% agarose native gels (Ciba Corning).
Metabolic studies
Radioiodinated lipoproteins in saline were injected via a tail vein. Blood was drawn from the orbital sinus into heparin-coated tubes, and plasma was separated by low-speed centrifugation. Radioactivity in 10 l aliquots was quantified in a ␥ counter. The fractional catabolic rates (FCRs) were calculated using SAAM II (SAAM Institute, Seattle, WA).
Tissue uptake of proteins labeled with TC was examined in mice housed in metabolic cages (four mice per cage). One day after injection of radiotracer, the mice were anesthetized and bled from the inferior vena cava immediately followed by perfusion with saline. Unless stated otherwise, organs were removed whole, weighed, and counted. Tissue samples were taken from visceral adipose tissue, muscle from the hind leg, and skin from the abdomen. These samples were weighed and counted. The accumulations of radiotracer in skin, muscle, and adipose tissue were calculated by assuming that these tissues accounted for 16.5, 38.4, and 6.4% (w/w), respectively, of the mass of a mouse (24) . Feces and urine were collected and counted. The injected dose was calculated using the plasma counts at 5 min as follows: (counts per minute per milliliter of plasma at 5 min) ϫ (mouse weight in grams) ϫ (0.035 ml of plasma per gram of mouse body weight). The counts remaining in the plasma at 24 h were calculated as follows: (counts per minute per milliliter of plasma at 24 h) ϫ (mouse weight in grams) ϫ (0.035 ml of plasma per gram of mouse body weight). The tissue distribution of radiotracer is expressed as a percentage of the injected dose.
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Statistical analysis
All statistical analyses were performed using the unpaired twotailed Student's t -test.
RESULTS
Analysis of radiolabeled Lp[a] and LDL
Lipoproteins were either radiolabeled directly by the iodine monochloride method (4) or, alternatively, radiolabeled TC was chemically cross-linked to lipoproteins by the method of Pittman and Taylor (23) . For each study, lipoprotein preparations were analyzed by SDS-PAGE under reducing and nonreducing conditions. A representative gel is shown in Fig. 1A . The Lp[a] used in this study had a single apo [a] isoform with the same apparent molecular weight as apoB-100, and this was verified by immunoblotting (data not shown). Nondenaturing agarose gel electrophoresis was also performed (Fig. 1B) , and for all preparations, a single band with pre ␤ mobility was observed. Lipoproteins labeled by either of the two methods showed essentially identical migration patterns when examined using both electrophoretic methods. The 125 I-TC-Lp[a] contained ‫ف‬ 10% of the label on apo[a] and the remainder on apoB-100 (data not shown).
Tissue uptake of Lp[a] and LDL in wild-type mice
To assess which organs or tissues were responsible for Lp[a] uptake and catabolism, male C57BL/6 mice were injected simultaneously with both 125 As expected, the tissue distribution of 131 I-LDL and 131 ILp[a] that lacked the trapped TC ligand was considerably different from that of the TC-labeled lipoproteins (Fig. 3) . The liver retained relatively little LDL and Lp[a] when these were not coupled to TC. Most of the labeled lipoprotein retained by tissues was found in the muscle and skin. The largest amount of radiolabel was recovered in the urine and accounted for 43% and 39% of the injected dose for LDL and Lp[a], respectively. This is an underestimation because there were some urine losses during some of the mouse bleeds. Indeed, in a similar study, when blood samples were not taken over the course of the urine collection, the radiolabel recovered in the urine accounted for almost all of the counts not recovered in the carcass when lipoproteins were labeled directly with iodine (data not shown).
To determine whether the 125 I-TC-Lp[a] injected into mice was still intact in the plasma after 24 h, plasma samples were adjusted to 7.5% (w/w) CsCl and ultracentrifuged to separate Lp[a] from LDL. Under these conditions, LDL floats near the top of the self-forming density gradient, whereas Lp[a] is found toward to the bottom. Figure 4 clearly shows that almost all of the radiolabel in the plasma after 24 h was found as intact Lp [a] . Free apo [a] , which would be found in the bottom of the tube, was not detected. 
Metabolism of Lp[a] and LDL in
The distribution of the trapped TC ligand among the tissues of the three mouse strains is shown in Table 1 . As shown previously for wild-type mice, the uptake of radiolabel by different tissues was very similar for TC-Lp 
Hepatic uptake of Lp[a] and LDL
Pittman and Taylor (23) showed in rat and in rabbit that trapped radiotracer from TC-labeled plasma protein did not redistribute between tissues after initial uptake, within 24 h after injection. However, they did detect significant leakage of radiolabel from the liver, which appeared in the gut contents and the feces. Because the liver is a major site for Lp [a] and LDL uptake in mice, we believe that radiotracer appearing in the gut contents and feces is probably hepatic in origin. Therefore, a better estimate for the hepatic uptake and catabolism of LDL and Lp [a] in mice would be obtained by adding the amounts recovered in the liver, gut contents, and feces. The net hepatic contribution to plasma clearance was calculated and expressed as a percentage of the injected dose (Fig. 6) . In these studies, the intestinal tissue and contents were not separated. We estimated the net hepatic clearance as the sum of the label found in the liver, intestine with contents, and feces. Because intestinal tissue contained only ‫%2ف‬ of the injected dose for both TC-LDL and TC-Lp[a] in wildtype mice, the error caused by including the intestinal tissue in the net hepatic uptake should be relatively small. In wild-type mice, the net hepatic uptake of TC-labeled LDL after 24 h was 41.7 Ϯ 2.3% of the injected dose. Hepatic uptake of TC-LDL was decreased by Ͼ2-fold in Ldlr Ϫ/Ϫ mice to 18.7 Ϯ 0.7% (P Ͻ 0.0001), whereas hepatic uptake in Apoe Ϫ/Ϫ mice was increased nearly 2-fold to 70.25 Ϯ 4.0% (P Ͻ 0.0001). In contrast, hepatic uptake of TCLp[a] showed a small decrease in Ldlr Ϫ/Ϫ mice to 27.9 Ϯ 1.3% compared with 34.6 Ϯ 3.1% in wild-type mice (P ϭ 0.003), and it increased in Apoe Ϫ/Ϫ mice to 39.33 Ϯ 2.1% (P ϭ 0.04).
Plasma clearance and tissue uptake of apo[a]
Apo[a] that was purified from Lp[a] had the same apparent molecular weight as apoB-100 when analyzed by SDS-PAGE under reducing conditions and, as expected, migrated considerably faster under nonreducing conditions (Fig. 3C) . The liver was the predominant site of apo[a] catabolism and retained 34.7 Ϯ 1.9% of the injected dose, whereas the kidney retained only 0.9 Ϯ 0.2%. The hepatic contribution to plasma clearance (liver ϩ intestinal contents ϩ feces) was 52.7%.
Apo[a] mediates the plasma clearance of Lp[a]
Because remained in the plasma after 30 min, whereas in mice injected with label only, 76.8 Ϯ 1.2% of the 125 I-TC-Lp[a] remained in the plasma (P ϭ 0.007). By 1 h, this effect was still apparent, with 93.5 Ϯ 5.6% of the label remaining in the plasma of mice coinjected with apo[a] compared with 65.7 Ϯ 3.3% in mice receiving label only (P ϭ 0.003).
To assess the contribution of the liver in the plasma clearance of Lp[a] during the first hour after injection, mice were injected with 125 I-TC-Lp[a] and at 1 h the animals were euthanized and perfused. After 1 h, 39.6 Ϯ 3.5% of the injected dose was cleared from the plasma and 10.5% of the injected dose was recovered in the liver (Fig. 8) . The spleen and kidney contained 0.6 Ϯ 0.3% and 0.7 Ϯ 0.1% of the injected dose, respectively.
Apo[a] is a highly glycosylated protein rich in sialic acid, and it has been suggested by Hrzenjak et al. (25) that the ASGPR found in the liver may play an important role in the plasma clearance of Lp [a] . We examined the clearance of 125 I-TC-Lp[a] and 125 I-TC-asialofetuin, an ASGPR ligand, in both the presence and absence of excess unlabeled asialofetuin (Fig. 7B ). Mice were injected with 60 g each of labeled Lp[a] and asialofetuin, either with or without 7.5 mg of asialofetuin. The plasma clearance of asialofetuin is very rapid, so that the initial plasma sample ϭ 7) , Ldlr Ϫ/Ϫ (n ϭ 4), and Apoe Ϫ/Ϫ (n ϭ 3) mice were housed in separate metabolic cages. Animals were euthanized after 24 h, and the organs and tissue samples were collected. Plasma samples were also taken, and the results are shown in Fig. 4 . The results are expressed as percentages of the injected dose. Data for feces and urine are from pooled samples. t-tests were used to compare each tissue in the knockout lines with wild-type tissues.
a P Ͻ 0.0005. b P Ͻ 0.05. taken at 5 min occurs after most of the label has been cleared. To obtain meaningful data for the clearance of asialofetuin, we found it necessary to estimate the actual injected dose at time zero based upon the volume injected rather than use the 5 min time point. At 5 min, only 3.9 Ϯ 0.4% of the label remained in the plasma. In contrast, in those mice also injected with excess unlabeled asialofetuin, 95.3 Ϯ 2.8% of the injected label remained in the plasma after 5 min. The inhibitory effect is still clearly seen after 1 h. The plasma clearance of Lp[a] was essentially unaffected by the presence of asialofetuin over the 1 h study period.
DISCUSSION
Mice do not possess Lp[a], which has been described only in certain primates and hedgehogs (26) . Despite this limitation, studies using transgenic mice producing human Lp[a] have already contributed much to our understanding of Lp[a] synthesis (27) (28) (29) (30) and its role in atherosclerosis (31) (32) (33) . Furthermore, we believe that mice may also offer an attractive model for the study of Lp[a] catabolism, because they are able to clear the lipoprotein in a way that appears to be similar to that in humans. In this study, we examined the plasma clearance and tissue uptake of both human LDL and Lp[a] in mice. As we demonstrated previously in humans (3, 4, 21) , in wild-type mice the clearance of LDL is faster than that of Lp [a] , and the relative FCR of LDL to Lp[a] is similar to that in humans. In this study in mice, FCR values for LDL were ‫%02ف‬ higher than the values for Lp [a] , whereas in humans, FCR values were ‫%04ف‬ higher for LDL than for Lp [a] . The plasma clearance of Lp [a] has been examined in human subjects with homozygous familial hypercholesterolemia who lack LDLRs (21) . In the present study, the influence of LDLR deficiency in mice on Lp[a] turnover is remarkably similar to the results seen in humans ( Table  2) . In both species, LDLR deficiency reduces the LDL FCR to ‫%05ف‬ of normal, while only reducing the Lp[a] FCR by ‫%01ف‬ (a difference that in both the mouse and human studies was not statistically significant). Gabelli et al. (34) examined the plasma clearance of LDL in a human subject who was apoE-deficient and reported an FCR that was 100% greater than normal. Similarly, in Apoe Ϫ/Ϫ mice, the LDL FCR was increased by 58%. Thus, the plasma clearance of both human LDL and Lp [a] in mice resembles what occurs in humans, suggesting that the pathways of catabolism in these species are similar.
We used radioiodinated TC to examine the tissue uptake of both human LDL and Lp[a] in mice. For both lipoproteins, the liver was by far the major organ responsible for clearance, whereas the kidney retained only ‫%1ف‬ (Table 1) in the mice used in this study. They also found Ͻ1% of the injected dose retained by the kidney.
The kidney has been hypothesized to play a major role in Lp[a] metabolism. Patients with impaired renal function have increased plasma Lp[a] levels (7, 8, 36, 37) . In addition, Kronenberg et al. (9) found arteriovenous differences in Lp[a] plasma concentrations, indicating that Lp[a] was removed from the renal circulation in these patients. Several studies have identified large apo[a] fragments in human urine (7, 38, 39) , and evidence suggests that these fragments are formed extrarenally and excreted by the kidney (38, 40, 41) . In our study, ‫%7ف‬ of the injected radiolabel from 125 I-TC-Lp[a] was found in the urine after 24 h (Table 1) , and only ‫%01ف‬ of the radiolabel was TCAprecipitable (data not shown). We did not detect any fragmentation of Lp[a] in the plasma. Mooser et al. (38) injected human Lp[a] into mice and detected only trace amounts in the urine by ELISA, and they detected no apo[a] fragments in either the urine or plasma by immunoblot analysis. Thus, in mice with normal renal function, the kidney does not play a major role in Lp[a] catabolism.
It has been proposed that Lp[a] is a ligand for the LDLR and that the liver plays a prominent role in plasma clearance of Lp[a] through the LDLR pathway. Although some in vitro studies support this proposal (11-13), others do not (42) (43) (44) . In addition, several studies have reported that individuals with familial hypercholesterolemia, in which there is a genetic absence of functional LDLRs, have increased plasma Lp[a] levels, suggesting a role for the LDLR and the liver in the plasma clearance of Lp[a] (10, 14, 15 [a] was ‫%9ف‬ less and hepatic uptake was reduced by ‫%02ف‬ during 24 h. On the other hand, for LDL, the FCR was reduced by ‫%05ف‬ and the hepatic uptake was less than half that for wild-type mice. Thus, it is possible that in wild-type mice the LDLR may make a minor contribution to the hepatic uptake of Lp [a] but that its role is much more limited than it is in the uptake of LDL.
ApoE can associate with apoB-containing lipoproteins and facilitate receptor-mediated endocytosis by several receptors in the LDLR family (19) . In addition, van Barlingen et al. (20) showed that enrichment of Lp[a] with apoE resulted in increased lipoprotein lipase-enhanced binding to heparan sulfate proteoglygans, concluding that the secretion-capture process of apoE was a possible catabolic route for Lp [a] . We examined the possible role of apoE in the catabolism of Lp [a] . In mice deficient in apoE, the plasma clearance of Lp[a] was slightly accelerated compared with that in wild-type mice (Fig. 5B) , and there was a small increase in hepatic uptake (Fig. 6A) . This suggests that Lp[a] catabolism is not primarily facilitated through the acquisition of apoE. In these mice, plasma clearance and hepatic uptake of LDL were greatly (Figs. 5A, 6B) . Woollett et al. (49) made similar observations when they examined the catabolism of both mouse and human LDL in Apoe Ϫ/Ϫ mice. Their studies revealed that the increased catabolism of LDL was not attributable to an increase in hepatic LDLRs but rather to the lack of apoE-containing lipoproteins to compete for binding to the receptor.
Other members of the LDLR family have also been suggested to participate in Lp[a] catabolism. It has been shown that the VLDL receptor mediates the uptake and catabolism of Lp [a] in fibroblasts expressing the VLDL receptor and that this uptake is mediated by apo[a] (18) . Furthermore, the plasma clearance of Lp[a] was delayed in VLDL receptor knockout mice. However, the VLDL receptor is found primarily in the heart, muscle, and adipose tissue (50) and is expressed only at very low levels in the liver. Hence, the VLDL receptor may play an important role in the apo[a]-mediated clearance of Lp[a] in certain nonhepatic tissues. Another candidate receptor, megalin/gp330, can mediate the uptake and degradation of Lp [a] in in vitro studies (16) , but unlike the VLDL receptor, the uptake is primarily mediated by apoB-100. However, megalin/gp330 is found only in certain resorptive epithelial cells, such as the proximal tubules of the kidney, and is not found in the liver (51) . Hence, it is unlikely that the VLDL receptor or megalin/gp330 participates significantly in the hepatic uptake of Lp [a] . The LRP is highly expressed by the liver, and one in vitro study suggested that it may act as a receptor for high molecular weight isoforms of Lp[a] (17), but other in vitro studies do not support this notion (44, 52) . It is well known that the LRP can mediate the hepatic catabolism of chylomicron and VLDL remnants containing apoE (24) . However, because apoE deficiency in mice did not reduce the hepatic uptake of 125 (53) , and if desialylated it is a possible ligand for the ASGPR, which is highly expressed in hepatocytes (54) . Asialofetuin is a well-characterized ligand of the ASGPR that is rapidly cleared from the plasma by the liver (55) . We found that asialofetuin at concentrations that greatly reduced its own plasma clearance rate had no effect on Lp[a] clearance. Hrzenjak et al. (25) showed that asialo Lp[a] is rapidly cleared from the plasma of mice and hedgehogs. In addition, they showed that in ASGPR-deficient mice the plasma clearance of native (57) suggested the existence of one or more receptors in the liver that bind to Lp[a] through the kringle IV 5-8 region of apo [a] and that also mediate the plasma clearance of remnant lipoproteins.
In this study, we used Lp[a] possessing a single isoform of apo [a] with the same apparent molecular weight as apoB-100. It is possible that the catabolism of other isoforms may be somewhat different. However, the FCR is independent of isoform size in humans (3), and presumably the sites of tissue uptake are independent of isoform size as well. We believe that this is probably also true for mice, although that issue was not addressed in this study.
In conclusion, we demonstrate that the liver is the primary organ responsible for the uptake and catabolism of Lp[a] in mice, whereas the kidneys are responsible for only a small fraction of the tissue uptake. Neither the LDLR nor apoE plays an important role in the hepatic uptake of Lp [a] . We show that a large molar excess of apo[a] dramatically reduces the plasma clearance of Lp [a] , which suggests that the apo[a] moiety plays a major role in mediating the plasma clearance and tissue uptake of Lp [a] . The nature of the major receptor(s) that mediate the plasma clearance and tissue uptake of Lp[a] remains to be determined.
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